Remaining Performance Obligations Certain of the Company's master services agreements or other arrangements contain take-or-pay clauses, whereby customers are required to purchase a fixed minimum quantity of product during a specified period, or pay the Company for such orders, even if not requested by the customer. The Company considers these take-or-pay clauses to be an enforceable contract, and as such, the legally-enforceable minimum amounts under such an arrangement are considered to be outstanding per ...

The Chemours Company (NYSE:CC) Q1 2023 Results Conference Call April 28, 2023 8:00 AM ET Company Participants Jonathan Lock - SVP and Chief Development Officer Mark Newman - CEO, President and Director Sameer Ralhan - Senior VP and CFO Conference Call Participants Duffy Fischer - Goldman Sachs Hassan Ahmed - Alembic Global Advisors John McNulty - BMO Capital Markets James Cannon - UBS Arun Viswanathan - RBC Capital Markets John Roberts - Credit Suisse William Tang - Morgan Stanley Laurence Alexander - Jeffe ...

Purchases of property, plant, and equipment included in accounts payable $ 34 $ 37 Treasury Stock repurchased, not settled — 6 Note 1. Background, Description of the Business, and Basis of Presentation Certain prior period amounts have been reclassified to conform to the current period presentation, the effect of which was not material to the Company's interim consolidated financial statements. Recently Adopted Accounting Guidance Disclosure of Supplier Finance Program Obligations Note 3. Net Sales 9 Substa ...

The Chemours Company (NYSE:CC) Q4 2022 Earnings Conference Call February 10, 2023 8:00 AM ET Company Participants Jonathan Lock - Senior Vice President and Chief Development Officer Mark Newman - President and Chief Executive Officer Sameer Ralhan - Senior Vice President and Chief Financial Officer Conference Call Participants Duffy Fischer - Goldman Sachs Arun Viswanathan - RBC Capital Markets John McNulty - BMO Capital Markets Matthew DeYoe - Bank of America Securities Josh Spector - UBS Hassan Ahmed - Al ...

Fourth Quarter & Full Year 2022 Earnings Presentation February 9, 2023 We prepare our financial statements in accordance with Generally Accepted Accounting Principles ("GAAP"). Within this presentation we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Adjusted Effective Tax Rate, Return on Invested Capital (ROIC) and Net Leverage Ratio which are non-GAAP financial measures. The company includes these non-GAAP financial measures because manag ...

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36794 1007 Market Street, Wilmington, Delaware 19801 (Address of Principal Executive Offices) Registrant's Telephone Number: (302) 773-1000 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Exchange on Wh ...

The Chemours Company (NYSE:CC) Q3 2022 Earnings Conference Call October 26, 2022 8:00 AM ET Company Participants Jonathan Lock - SVP & Chief Development Officer Mark Newman - President & CEO Sameer Ralhan - SVP & CFO Conference Call Participants Duffy Fischer - Goldman Sachs Arun Viswanathan - RBC Capital Markets John McNulty - BMO Capital Markets Mike Leithead - Barclays Matthew DeYoe - Bank of America James Cannon - UBS Hassan Ahmed - Alembic Global Advisors William Tang - Morgan Stanley Kevin Estok - Jef ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36794 The Chemours Company (Exact Name of Registrant as Specified in Its Charter) Delaware 46-4845564 (State or other Jurisdiction of Incorporation or Organization) (I.R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36794 The Chemours Company (Exact Name of Registrant as Specified in Its Charter) Delaware 46-4845564 (State or other Jurisdiction of Incorporation or Organization) (I.R.S. E ...

The Chemours Company (NYSE:CC) Q2 2022 Earnings Conference Call July 29, 2022 8:30 AM ET Company Participants Mark Newman - President, Chief Executive Officer Sameer Ralhan - Senior Vice President, Chief Financial Officer Jonathan Lock - Senior Vice President, Chief Development Officer Conference Call Participants Arun Viswanathan - RBC Capital Markets Ross Huffman - Bank of America John McNulty - BMO Capital Markets Mike Leithead - Barclays Josh Spector - UBS Vincent Andrews - Morgan Stanley Kevin Estok - ...